COVID-19: NIH begins large clinical trial
Washington – The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which … Continue reading COVID-19: NIH begins large clinical trial
Investigational COVID-19 vaccine well-tolerated
Washington – A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of … Continue reading Investigational COVID-19 vaccine well-tolerated
Experimental coronavirus vaccine is safe
Washington – Researchers are working to develop a safe and effective vaccine against SARS-CoV-2, the novel coronavirus that causes COVID-19. Before a vaccine is available to the public, it must go through several stages of testing. The first stage is … Continue reading Experimental coronavirus vaccine is safe
Clinical trials of monoclonal antibodies now enrolling
Washington – Two Phase 3, randomized, placebo-controlled, double-blind clinical trials testing whether experimental monoclonal antibodies (mAbs) can prevent infection by SARS-CoV-2 coronavirus are now enrolling healthy adults at clinical trial sites in the United States. Many of the trial sites … Continue reading Clinical trials of monoclonal antibodies now enrolling
Experimental vaccine generates immune response
Washington – An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New … Continue reading Experimental vaccine generates immune response